Amir Mahmoud Ahmadzadeh, Nima Broomand Lomer, Mohammad Amin Ashoobi, Danial Elyassirad, Benyamin Gheiji, Mahsa Vatanparast, Seyed Ali Jalalian, Mehdi Arab, Farrokh Seilanian Toosi, Girish Bathla, Shahriar Faghani
{"title":"Predicting 1p/19q Codeletion Status in Glioma Using MRI-Derived Radiomics; A Systematic Review and Meta-Analysis of Diagnostic Accuracy.","authors":"Amir Mahmoud Ahmadzadeh, Nima Broomand Lomer, Mohammad Amin Ashoobi, Danial Elyassirad, Benyamin Gheiji, Mahsa Vatanparast, Seyed Ali Jalalian, Mehdi Arab, Farrokh Seilanian Toosi, Girish Bathla, Shahriar Faghani","doi":"10.3174/ajnr.A8771","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The 1p/19q codeletion is a key genetic marker in gliomas and plays a crucial role in prognosis and treatment decisions. Traditional methods for detecting this genetic alteration rely on invasive tissue biopsies.</p><p><strong>Purpose: </strong>This systematic review and meta-analysis aimed to evaluate the performance of magnetic resonance imaging (MRI)-derived radiomics-based models to predict glioma 1p/19q codeletion status.</p><p><strong>Data sources: </strong>A literature search was conducted in four databases-PubMed, Web of Science, Embase, and Scopus.</p><p><strong>Study selection: </strong>We selected the studies that assessed the performance of radiomics-based models in determining 1p/19q codeletion status.</p><p><strong>Data analysis: </strong>The METhodological RadiomICs Score (METRICS) was used to evaluate study quality. Pooled diagnostic estimates were calculated, and heterogeneity was assessed using the I<sup>2</sup> statistic. Subgroup and sensitivity analyses were performed to investigate potential sources of heterogeneity. Deeks' funnel plot was used to assess publication bias.</p><p><strong>Data synthesis: </strong>Twenty-eight studies met the inclusion criteria for the systematic review. A meta-analysis of 10 studies yielded a pooled sensitivity of 0.82 (95% CI: 0.67-0.91), specificity of 0.80 (95% CI: 0.70-0.88), positive diagnostic likelihood (DLR) of 4.14 (95%CI: 2.62-6.52), negative DLR of 0.23 (95% CI: 0.12-0.43), diagnostic odds ratio of 18.37 (95% CI: 7.36-45.85), and area under the curve of 0.87 (95% CI: 0.84-0.90). Subgroup analysis revealed significant differences based on the country and segmentation method.</p><p><strong>Limitations: </strong>Our meta-analysis is limited by small number of studies with external validation cohorts.</p><p><strong>Conclusions: </strong>MRI-derived radiomics-based models demonstrated good predictive performance for glioma 1p/19q codeletion status, highlighting their potential as a non-invasive tool for glioma characterization and for aiding in treatment decision-making.</p><p><strong>Abbreviations: </strong>DLR: diagnostic likelihood ratio, DOR: diagnostic odds ratio, AUC =area under the curve; HOIV: holdout internal validation, EV = external validation.</p>","PeriodicalId":93863,"journal":{"name":"AJNR. American journal of neuroradiology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJNR. American journal of neuroradiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3174/ajnr.A8771","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The 1p/19q codeletion is a key genetic marker in gliomas and plays a crucial role in prognosis and treatment decisions. Traditional methods for detecting this genetic alteration rely on invasive tissue biopsies.
Purpose: This systematic review and meta-analysis aimed to evaluate the performance of magnetic resonance imaging (MRI)-derived radiomics-based models to predict glioma 1p/19q codeletion status.
Data sources: A literature search was conducted in four databases-PubMed, Web of Science, Embase, and Scopus.
Study selection: We selected the studies that assessed the performance of radiomics-based models in determining 1p/19q codeletion status.
Data analysis: The METhodological RadiomICs Score (METRICS) was used to evaluate study quality. Pooled diagnostic estimates were calculated, and heterogeneity was assessed using the I2 statistic. Subgroup and sensitivity analyses were performed to investigate potential sources of heterogeneity. Deeks' funnel plot was used to assess publication bias.
Data synthesis: Twenty-eight studies met the inclusion criteria for the systematic review. A meta-analysis of 10 studies yielded a pooled sensitivity of 0.82 (95% CI: 0.67-0.91), specificity of 0.80 (95% CI: 0.70-0.88), positive diagnostic likelihood (DLR) of 4.14 (95%CI: 2.62-6.52), negative DLR of 0.23 (95% CI: 0.12-0.43), diagnostic odds ratio of 18.37 (95% CI: 7.36-45.85), and area under the curve of 0.87 (95% CI: 0.84-0.90). Subgroup analysis revealed significant differences based on the country and segmentation method.
Limitations: Our meta-analysis is limited by small number of studies with external validation cohorts.
Conclusions: MRI-derived radiomics-based models demonstrated good predictive performance for glioma 1p/19q codeletion status, highlighting their potential as a non-invasive tool for glioma characterization and for aiding in treatment decision-making.
Abbreviations: DLR: diagnostic likelihood ratio, DOR: diagnostic odds ratio, AUC =area under the curve; HOIV: holdout internal validation, EV = external validation.